{
  "issued_date": "2013-09-16", 
  "original_url": "http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON314933", 
  "doc_details": {
    "Type": "Drug Alert", 
    "Series No": "EL (13)A/22", 
    "Audience": "Healthcare professionals", 
    "Published": "16 September 2013", 
    "Format": "Electronic", 
    "Size": "A4", 
    "Pages": "1", 
    "Price": "Free", 
    "ISBN/ISSN": "", 
    "Author": "", 
    "Copyright": "Crown"
  }, 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": " Class 2 Drug Alert (Action Within 48 Hours): Bydureon 2mg powder and solvent for prolonged-release suspension for injection - Eli Lilly Nederland B.V.- EL (13)A/22 (203Kb)", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/is-md/documents/drugalert/con314935.pdf", 
      "filename": "downloads/44f2a3c7521d31dcaa695a843cab6bd68cb7972e/con314935.pdf", 
      "original_filename": "con314935.pdf"
    }
  ], 
  "body": "## DRUG ALERT\n\nCLASS 2 MEDICINES RECALL\n\nAction Within 48 Hours\n\n  \n\n\nPharmacy, Clinic and Wholesaler Level Recall  \n  \n16 September 2013  |   |  EL (13)A/22  |   |  Our ref:\u00a0 MDR 14-09/13   | \n\n* * *\n\nDear Healthcare Professional,\n\nEli Lilly Nederland B.V.\n\nBYDUREON 2mg powder and solvent for prolonged-release suspension for injection\n\n(Exenatide)\n\nEU/1/11/696/001\n\n  \n  \n  \nBatch number  |   |  Expiry date  |   |  Pack size  |   |  First distributed  |   \nC164827  |   |  31 August 2015  |   |  4 x 1 single-dose kit (1 vial + 1 syringe)  |   |  12 July 2013  | \n\n  \n\n\nBristol-Myers Squibb and Astra Zeneca, who, following a recent change of ownership, are now Marketing Authorisation holders for the Bydureon (Exenatide) product licence range, are recalling the above batch of Bydureon to pharmacy, clinic and wholesaler level, following an in-depth review of manufacturing records which indicated that this batch may contain a very small number of under filled vials.\u00a0 The low fills impact approximately 0.2% of the batch and range between 30% and 75% of the labeled dose.\n\nRemaining stocks of the affected batch should be quarantined and returned to the original supplier for credit.\u00a0 For enquiries relating to stock returns please contact your original suppliers local service center.\n\nFor medical information enquiries please contact BMS by phone on 0800 731 1736 or by email to [medical.information@bms.com](mailto:%20medical.information@bms.com).\n\nRecipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Local area teams are asked to forward this to relevant clinics, general practitioners and community pharmacists for information.\n\nYours faithfully\n\nAlison Bunce  \nPharmaceutical Assessor  \nDefective Medicines Report Centre  \n151 Buckingham Palace Road  \nLondon  \nSW1W 9SZ  \nTelephone +44 (0)20 3080 6574\n\n  \nMHRA Distribution (further recipients by cascade):  . \n\n### Download documents:  \n  \n  * [ASSET_TAG](#ASSET0)\n", 
  "raw_html": "<div class=\"inner\">          \r\n\t\t\t\t<a name=\"main\"></a>\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"title\">\r\n\t\t\t\t\t<h2>DRUG ALERT</h2>\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element14)-->\r\n\t\t\t\t\t<p>CLASS 2 MEDICINES RECALL</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element14)-->\r\n\t\t\t\t</div>\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"drugalertdetails\">\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element15)-->\r\n\t\t\t\t\t<p>Action Within 48 Hours</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element15)-->\r\n\t\t\t\t\t<br>\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element16)-->\r\n\t\t\t\t\t<p>Pharmacy, Clinic and Wholesaler Level Recall</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element16)-->\r\n\t\t\t\r\n\t\t\t\t\t<table id=\"dateref\">\r\n\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t<td align=\"left\">\r\n\t\t\t\t\t\t\t\r\n\r\n\t\t\t\t\t\t\t16 September 2013\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<td>\r\n\t\t\t\t\t\t\tEL (13)A/22\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<td align=\"right\">\r\n\t\t\t\t\t\t\t\tOur ref:&#160;\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element17)-->\r\n\t\t\t\t\t\t\t\t MDR 14-09/13 \r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element17)-->\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t</table>\r\n\t\t\t\t</div>\r\n\t\t\t\t<hr>\t\t\t\t\r\n          \t\t<!--SS_BEGIN_ELEMENT(region1_element12)-->\r\n          \t\t<!--SS_END_ELEMENT(region1_element12)--> \r\n          \t\t\r\n          \t\t \r\n          \t\t\r\n          \t\t<p>Dear Healthcare Professional,</p>\r\n\r\n\t\t\t\t<div class=\"druginfo\">\r\n\t\t\t\t\t<div class=\"left\">\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Eli Lilly Nederland B.V.</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\t\t\t\t\r\n          \t\t          \t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>BYDUREON 2mg powder and solvent for prolonged-release suspension for injection</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>(Exenatide)</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</div>\r\n\t\t\t\t\t\r\n\t\t\t\t\t<div class=\"right\">\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<span>EU/1/11/696/001</span>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</div>\t\r\n\t\t\t\t</div>\t\t\t\t\r\n          \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment8,navigation_controls)-->\r\n\t\t\t\t<!-- only show the publication navigation controls if there is more than one page to the publication -->\r\n\t\t\t\r\n\t\t\t\t<!-- SS_END_SNIPPET(fragment8,navigation_controls)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(region1_element2,paged_publication)-->\r\n        \t\t<!-- <br>SS_DATAFILE: CON314933 -->\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<p><br>\n</p><table border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tr>\n<td width=\"156\" valign=\"top\">\n <span>Batch number</span>\n</td>\n<td width=\"164\" valign=\"top\">\n <span>Expiry date</span>\n</td>\n<td width=\"164\" valign=\"top\">\n <span>Pack size</span>\n</td>\n<td width=\"174\" valign=\"top\">\n <span>First distributed</span>\n</td>\n</tr>\n\n<tr>\n<td width=\"156\">\n C164827 \n</td>\n<td width=\"164\">\n 31 August 2015 \n</td>\n<td width=\"164\">\n 4 x 1 single-dose kit  \n(1 vial + 1 syringe)\n</td>\n<td width=\"174\">\n 12 July 2013 \n</td>\n</tr>\n</table>\n\n<br>\n<p>Bristol-Myers Squibb and Astra Zeneca, who, following a recent change of ownership, are now Marketing Authorisation holders for the Bydureon (Exenatide) product licence range, are recalling the above batch of Bydureon to pharmacy, clinic and wholesaler level, following an in-depth review of manufacturing records which indicated that this batch may contain a very small number of under filled vials.&#160; The low fills impact approximately 0.2% of the batch and range between 30% and 75% of the labeled dose.</p>\n\n<p>Remaining stocks of the affected batch should be quarantined and returned to the original supplier for credit.&#160; For enquiries relating to stock returns please contact your original suppliers local service center.</p>\n\n<p>For medical information enquiries please contact BMS by phone on 0800 731 1736 or by email to <a href=\"mailto:%20medical.information@bms.com\">medical.information@bms.com</a>.</p>\n\n<p>Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Local area teams are asked to forward this to relevant clinics, general practitioners and community pharmacists for information.</p>\n\n<p align=\"left\">Yours faithfully</p>\n\n<p align=\"left\"><span>Alison Bunce<br>\nPharmaceutical Assessor<br>\nDefective Medicines Report Centre<br>\n151 Buckingham Palace Road<br>\nLondon<br>\nSW1W 9SZ<br>\nTelephone +44 (0)20 3080 6574</span></p>\n\n<br>\r\n\r\n\t\t\t\r\n        \t\t<!-- SS_END_SNIPPET(region1_element2,paged_publication)-->\r\n        \t\t\r\n        \t\tMHRA Distribution (further recipients by cascade):\r\n        \t\t\r\n        \t\t <!--SS_BEGIN_ELEMENT(region1_element18)-->\r\n        \t\t.\r\n        \t\t<!--SS_END_ELEMENT(region1_element18)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(region1_element3,static_pdf_list)-->\r\n        \t\t<!-- the xmlListTag variable is used by the searchDocsByContentIdList include to map the name of the XML node which contains the content id -->\r\n<!--perform the search -->\r\n\t\r\n\t<!-- <br>root: Content/AssociatedContent -->\r\n\t<!-- <br>ssFragmentInstanceId: region1_element3\t -->\r\n\t<!-- <br>SS_DATAFILE: CON314933 -->\r\n\t<!-- <br>xmlListTag: ContentId\t -->\r\n\t<!-- <br>XPATH: CON314933/Content/AssociatedContent/ContentId\t -->\r\n\r\n\t<!-- xmlListTag variable should be the name of the xml node which contains a contentid.  there should be a lis of these in the XML -->\r\n\t<!-- <br>strNumRecords: 1 -->\r\n\t<!-- <br>nNumRecords: 1 -->\r\n\r\n\t\t\t<!-- using the content ID above, get the docment from conetent server-->\r\n\r\n\t\t\t\r\n\r\n\t\t<!--  dDocName <matches>`CON314935` -->\r\n\t\t\r\n<div id=\"downloadArea\">\r\n\t<h3>Download documents:</h3>\r\n\t<ul>\r\n\t\t<!-- the SearchResults will have been initialised by the call to searchDocsByContentIdList above-->\r\n\t\t\t\r\n\t\t\t\t<li>\r\n\r\n\t\t\t\t\t\t<a href=\"#ASSET0\">ASSET_TAG</a>\r\n\t\t\t\t</li>\r\n\t</ul>\r\n\t<div class=\"clearing\"><!--  --></div>\r\n\t<!--<p><a class=\"doubleArrow\" target=\"new\" href=\"http://www.adobe.com/products/acrobat/readstep2.html\">Download Acrobat Reader for free</a></p>\r\n\t<p><a class=\"doubleArrow\" target=\"new\" href=\"http://www.adobe.com/products/acrobat/access_onlinetools.html\">Adobe text conversion tools</a></p>-->\r\n</div>\r\n\t\t\t\r\n        \t\t<!-- SS_END_SNIPPET(region1_element3,static_pdf_list)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_CLOSEREGIONMARKER(region1)-->\r\n        \t\t\r\n        \t\t<!-- SS_END_CLOSEREGIONMARKER(region1)-->\r\n\t\t\t</div>\r\n\t\t", 
  "title": "Class 2 Drug Alert (Action Within 48 Hours): Bydureon 2mg powder and solvent for prolonged-release suspension for injection - Eli Lilly Nederland B.V. (EL (13)A/22)", 
  "alert_type": [
    "drugs"
  ], 
  "medical_specialism": []
}